1. INTRODUCTION
1.1. Market Overview
1.2. COVID-19 Scenario
1.3. Market Definition
1.4. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. MONOCLONAL ANTIBODY MARKET, BY INDICATION
5.1. Introduction
5.2. Inflammatory Disease
5.3. Cancer
5.4. Microbial Disease
5.5. Others
6. MONOCLONAL ANTIBODY MARKET, BY SOURCE
6.1. Introduction
6.2. Humanized
6.3. Human
6.4. Chimeric
6.5. Murine
7. MONOCLONAL ANTIBODY MARKET, BY Application
7.1. Introduction
7.2. Diagnostic
7.3. Therapeutic
7.4. Others
8. MONOCLONAL ANTIBODY MARKET, BY END-USER
8.1. Introduction
8.2. Hospitals & Clinic
8.3. Research Laboratories
9. MONOCLONAL ANTIBODY MARKET, BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. USA
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. Germany
9.4.2. France
9.4.3. United Kingdom
9.4.4. Spain
9.4.5. Others
9.5. Middle East and Africa
9.5.1. Saudi Arabia
9.5.2. UAE
9.5.3. Others
9.6. Asia Pacific
9.6.1. China
9.6.2. Japan
9.6.3. South Korea
9.6.4. India
9.6.5. Thailand
9.6.6. Taiwan
9.6.7. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix
11. COMPANY PROFILES
11.1. Eli Lilly and Company
11.2. AbbVie, Inc.
11.3. Novartis AG
11.4. Bristol Myers Squibb
11.5. F. Hoffmann-La Roche Ltd.
11.6. Johnson & Johnson Services, Inc.
11.7. Amgen Inc.
11.8. Merck & Co. Inc.
11.9. AstraZeneca PLC
LIST OF FIGURES
LIST OF TABLES